News
Chiesi reinforces commitment to reducing emissions
In 2019, Chiesi committed €350m to develop the first carbon minimal pressurised metered dose inhaler (pMDI) to treat asthma and Chronic Obstructive Pulmonary Disease (COPD) by 2025, replacing the current hydrofluorocarbon propellant with a new propellant.